Evolution and comparison effects of Fludrocortisone and Betamethasone on Glucose and lipid profile in rats

  • Hamid Reza Jamshidi 09126014975
  • Mohammad Naeem Malmir
Keywords: Fludrocortisone, Betamethasone, Fat Profile, Glucose, Type 2 Diabetes

Abstract

Introduction: Hyperglycemia may associate with improper use of glucocorticoids, impaired insulin function, or both, and is associated with many complications such as hyperlipidemia and Hyperglycemia. Researches suggests that proper use of glucocorticoids, can delay the onset and progression of complications of hyperglycemia and hyperlipidemia. In the present study we compare two of these compounds on glucose and lipid profile level. Methods: we use 40 male Wistar rats from Yazd Animal infertility center. Initially, the rats were randomly divided into 2 groups and then each group was divided into 4 groups. Subsequently, fludrocortisone doses of 12, 24 and 36 mg / kg were administered to rats, and dosages of 6, 12 and 18 mg / kg for betamethasone administered to rats on a daily basis at 1 o'clock for 21 days by intraperitoneally injection. Results: Betamethasone and Fludrocortisone increased blood glucose and AST, ALT, TG, LDL, VLDL, and decreased HDL, causing red pigmentation in the skin, and obesity and puffiness of the rats. In all of the measured factors, fludrocortisone changes were more than betamethasone. Fludrocortisone and betamethasone also had significant effects on weight, which was more pronounced with fludrocortisone. Conclusion: As the dose increased, the levels of AST, ALT, and cholesterol, TG, VLDL and LDL in the blood increased significantly and HDL levels decreased more in the blood, but fludrocortisone showed a stronger effect than betamethasone. Therefore, it can be expected that the use of Betamethasone would be logical due to fewer side effects than fludrocortisone.

References

1.Bangstad HJ, Danne T, Deeb LC, Jarosz-Chobot P, Urakami T, Hanas R. ISPAD Clinical Practice Consensus Guidelines 2006-2007. Insulin treatment. Pediatric diabetes. 2007 Apr;8(2):88-102.
2.van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes technology & therapeutics. 2011 Jun;13(6):607-14.
3.Gibney M, Xue Z, Swinney M, Bialonczyk D, Hirsch L. Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies. Diabetes technology & therapeutics. 2016 Mar;18(3):136-43.
4.Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.
5.Upadhyay R, Ding H. Differential role of microRNAs miR-221/222 and miR-103/107 in type 2 diabetes and effects of metformin2014. 851.2 p.
6.Catalan V, Gomez-Ambrosi J, Rodriguez A, Silva C, Rotellar F, Gil MJ, et al. Expression of caveolin-1 in human adipose tissue is upregulated in obesity and obesity-associated type 2 diabetes mellitus and related to inflammation. Clinical endocrinology. 2008 Feb;68(2):213-9.
7.Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care. 2004 Jul;27(7):1721-7.
8.Herman WH, Zimmet P. Type 2 diabetes: an epidemic requiring global attention and urgent action. Diabetes Care. 2012 May;35(5):943-4.
9.Raharinavalona SA, Ramalanjaona HR, Andrianera N, Patrick Rakotomalala AD, Ramahandridona G. Dépistage du risque podologique chez les diabétiques de type 2 à Antananarivo. The Pan African medical journal. 2017;27:213-.
10.Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010 Feb;33(2):442-9. PubMed PMID: 20103560.
11.Afkar A, Nezhad K, Shams M, Farmanbar R. A study of blood pressure prevalence and some of its effective factors in different ethnicities in the rural population2012.
12.Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. WHO2011.
13.Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. European heart journal. 1997 Aug;18(8):1231-48.
14.Gholami Fesharaki M, AzadMarzabadi E. Evaluation of the reliability and validity of Azad-Fesharaki's physical activity questionnaire (AFPAQ). HBI_Journals. 2011;14(3):36-44.
15.Lucassen EA, Cizza G. The Hypothalamic-Pituitary-Adrenal Axis, Obesity, and Chronic Stress Exposure: Sleep and the HPA Axis in Obesity. Current obesity reports. 2012 Dec;1(4):208-15. PubMed PMID: 23162786.
16.Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B. Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. The AAPS journal. 2017 May;19(3):727-35.
17.Nejat S, Montazeri A, Holakouie Naieni K, Mohammad K, Majdzadeh SR. The World Health Organization quality of Life (WHOQOL-BREF) questionnaire: Translation and validation study of the Iranian version. sjsph. 2006;4(4):1-12.
18.Schafer-Korting M, Kleuser B, Ahmed M, Holtje HD, Korting HC. Glucocorticoids for human skin: new aspects of the mechanism of action. Skin pharmacology and physiology. 2005 May-Jun;18(3):103-14. PubMed PMID: 15897682. Epub 2005/05/18.
19.Glick M. Burket's oral medicine2015.
20.Yadav SK, Acharya S. Dental Management Of The Medically Compromised Patient Management Of The Medically Compromised Dental Patient. 2012. English.
21.Su Y, Carey LC, Rose JC, Pulgar VM. Antenatal glucocorticoid exposure enhances the inhibition of adrenal steroidogenesis by leptin in a sex-specific fashion. American journal of physiology Endocrinology and metabolism. 2013 Jun 15;304(12):E1404-11.
22.Scully C. Orofacial herpes simplex virus infections: current concepts in the epidemiology, pathogenesis, and treatment, and disorders in which the virus may be implicated. Oral surgery, oral medicine, and oral pathology. 1989 Dec;68(6):701-10.
23.Feldman DM, Carbone J, Belden L, Borgida AF, Herson V. Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates. American journal of obstetrics and gynecology. 2007 Sep;197(3):284.e1-4.
24.Zhou M, Zhu L, Cui X, Feng L, Zhao X, He S, et al. The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio as a predictor of insulin resistance but not of β cell function in a Chinese population with different glucose tolerance status. Lipids in health and disease. 2016;15:104-.
25.Shokr M, Rashed A, Lata K, Kondur A. Dexamethasone Associated ST Elevation Myocardial Infarction Four Days after an Unremarkable Coronary Angiogram-Another Reason for Cautious Use of Steroids: A Case Report and Review of the Literature. Case reports in cardiology. 2016;2016:4970858-.
26.Ramirez-Torres MA, Perez-Monter SE, Espino y Sosa S, Ibarguengoitia-Ochoa F. [Effect of betamethasone in blood glucose levels in pregnant diabetic women at risk of preterm birth]. Ginecologia y obstetricia de Mexico. 2011 Sep;79(9):565-71.
Published
2020-02-15
How to Cite
1.
Jamshidi H, Malmir MN. Evolution and comparison effects of Fludrocortisone and Betamethasone on Glucose and lipid profile in rats. Acta Med Iran. 57(8):478-483.
Section
Articles